Placebo + Lumacaftor Plus Ivacaftor Combination + Ivacaftor
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Conditions
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Trial Timeline
Apr 1, 2013 → Apr 1, 2014
NCT ID
NCT01807949About Placebo + Lumacaftor Plus Ivacaftor Combination + Ivacaftor
Placebo + Lumacaftor Plus Ivacaftor Combination + Ivacaftor is a phase 3 stage product being developed by Vertex Pharmaceuticals for Cystic Fibrosis, Homozygous for the F508del CFTR Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT01807949. Target conditions include Cystic Fibrosis, Homozygous for the F508del CFTR Mutation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01807949 | Phase 3 | Completed |
Competing Products
20 competing products in Cystic Fibrosis, Homozygous for the F508del CFTR Mutation